سوق تشخيص سرطان المعدة في الشرق الأوسط وأفريقيا – اتجاهات الصناعة والتوقعات حتى عام 2030

Request for TOC طلب جدول المحتويات Speak to Analyst تحدث إلى المحلل Buy Now اشتري الآن Inquire Before Buying استفسر قبل Free Sample Report تقرير عينة مجاني

سوق تشخيص سرطان المعدة في الشرق الأوسط وأفريقيا – اتجاهات الصناعة والتوقعات حتى عام 2030

  • Healthcare IT
  • Published Report
  • Mar 2023
  • MEA
  • 350 الصفحات
  • عدد الجداول: 160
  • عدد الأرقام: 56

Middle East And Africa Gastric Cancer Diagnostics Market

حجم السوق بالمليار دولار أمريكي

CAGR :  % Diagram

Diagram فترة التنبؤ
2024 –2030
Diagram حجم السوق (السنة الأساسية)
مليون دولار أمريكي
Diagram حجم السوق (سنة التنبؤ)
USD 69.63
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

سوق تشخيص سرطان المعدة في الشرق الأوسط وأفريقيا، حسب نوع المنتج (الأدوات والكواشف والمواد الاستهلاكية والخدمات)، نوع التشخيص (الاختبار التأكيدي، اختبارات فحص سرطان المعدة / الفحص البدني)، الفئة العمرية (البالغين والأطفال وكبار السن)، نوع المرض (سرطان الغدة المعوية أو المنتشر، ورم كارسينويد، ورم ظهاري في الجهاز الهضمي (GIST)، ورم الغدد اللمفاوية المعدية وغيرها)، المرحلة (المرحلة 0، المرحلة الأولى، المرحلة الثانية، المرحلة الثالثة)، الجنس (ذكر وأنثى)، نوع العينة (الدم والأنسجة والبول والبراز)، المستخدمون النهائيون (مختبرات التشخيص والمستشفيات ومعاهد أبحاث السرطان والعيادات التخصصية للأورام وغيرها)، قناة التوزيع (العطاءات المباشرة ومبيعات التجزئة) - اتجاهات الصناعة والتوقعات حتى عام 2030.

سوق تشخيص سرطان المعدة في الشرق الأوسط وأفريقيا

تحليل ورؤى حول سوق تشخيص سرطان المعدة في الشرق الأوسط وأفريقيا

إن الزيادة في عدد السكان المسنين في الشرق الأوسط وأفريقيا هي المحرك لنمو صناعة تشخيص سرطان المعدة. كما أدى انتشار أورام الجهاز الهضمي والأورام اللمفاوية إلى زيادة الطلب على تشخيص سرطان المعدة. ويتمثل القيد الرئيسي للسوق في الحاجة إلى خفض الأسعار المرتفعة المرتبطة باختبارات تشخيص السرطان حتى تتمكن البلدان النامية من الاستفادة منها.

سوق تشخيص سرطان المعدة في الشرق الأوسط وأفريقياسوق تشخيص سرطان المعدة في الشرق الأوسط وأفريقيا

يقدم عدد كبير من اللاعبين في السوق منتجات تشخيص سرطان المعدة مع الابتكارات التي تمهد الطريق لنمو سوق تشخيص سرطان المعدة في الشرق الأوسط وأفريقيا.

تحلل شركة Data Bridge Market Research أن سوق تشخيص سرطان المعدة في الشرق الأوسط وأفريقيا من المتوقع أن تصل قيمته إلى 69.63 مليون دولار أمريكي بحلول عام 2030، بمعدل نمو سنوي مركب قدره 7.4% خلال الفترة المتوقعة. تشكل الكواشف والمواد الاستهلاكية أكبر شريحة من أنواع المنتجات في السوق بسبب الطلب المتزايد على الأدوات والكواشف، كما أدى زيادة الإنفاق الصحي إلى تسريع الطلب على الأجهزة الطبية الذكية.

تقرير القياس

تفاصيل

فترة التنبؤ

2023 إلى 2030

سنة الأساس

2022

سنوات تاريخية

2021 (قابلة للتخصيص حتى 2015-2020)

وحدات كمية

الإيرادات بالملايين من الدولارات الأمريكية، الأحجام بالوحدات، التسعير بالدولار الأمريكي

القطاعات المغطاة

حسب نوع المنتج (الأدوات والكواشف والمواد الاستهلاكية والخدمات)، نوع التشخيص (الاختبار التأكيدي، اختبارات فحص سرطان المعدة/الفحص البدني)، الفئة العمرية (البالغين والأطفال وكبار السن)، نوع المرض (سرطان غدي معوي أو منتشر، ورم كارسينويد، ورم ظهاري معدي معوي (GIST)، ورم الغدد الليمفاوية المعدية وغيرها)، المرحلة (المرحلة 0، المرحلة الأولى، المرحلة الثانية، المرحلة الثالثة)، الجنس (ذكر وأنثى)، نوع العينة (دم، أنسجة، بول، وبراز)، المستخدمون النهائيون (مختبرات التشخيص والمستشفيات ومعاهد أبحاث السرطان والعيادات التخصصية في الأورام وغيرها)، قناة التوزيع (العطاءات المباشرة ومبيعات التجزئة)

الدول المغطاة

المملكة العربية السعودية وجنوب أفريقيا والإمارات العربية المتحدة وإسرائيل ومصر وبقية دول الشرق الأوسط وأفريقيا

الجهات الفاعلة في السوق المشمولة

BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Biohit Oyj, DiaSorin S.p.A, Paragon Genomics, Inc., and QIAGEN among others

Market Definition

Stomach cancer is a type of cancer that starts in the stomach and spreads throughout the body. The stomach is a muscular pouch that lies immediately below the ribs in the upper part of the abdomen. The stomach takes in and holds the food we eat before breaking it down and digesting it. Stomach cancer, commonly referred to as gastric cancer, can occur in any section of the stomach. Stomach cancers develop in the major section of the stomach in most parts of the world (stomach body). Various diagnostic tests used for the diagnosis of cancer include prescreening tests, biopsy, biomarkers, imaging tests, PET/CT scans, and ultrasound among others.

Cancer is caused by uncontrolled, abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as gastric cancer or stomach cancer. Diet and stomach disorders are both risk factors for gastric cancer.

Middle East and Africa Gastric Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

 Drivers

  • Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma

According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide. Gastric cancer is responsible for about 1 in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed around the world.

It is projected that the incidence of gastric cancer will rise, due to to aging and increasing population, lifestyle, and socioeconomic change. Striking variations in race, sociocultural norms, behaviors, and dietary trends are reflected in the burden and distribution of cancer in different regions across the globe.

Thus, the rising incidence of cancers across the globe is expected to accelerate the demand for gastric cancer diagnostics. Thus the increased incidence rates of gastrointestinal tumors, lymphoma, and adenocarcinoma are expected to drive the growth of the Middle East and Africa gastric cancer diagnostics market.

  • Rise in alcohol consumption and surge in smoking

Epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone and so represents a severe public health issue that warrants further investigation.

A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.

Thus, the rise in alcohol consumption and surge in smoking is expected to drive the Middle East and Africa gastric cancer market growth.

Opportunity

  • Rise in adoption of automated systems

Cancer is a system and network illness. This indicates that in a cancer cell, certain network-related genes stop working properly. Complex interactions in such gene networks should be addressed in cancer treatment. Artificial intelligence (AI) algorithms, in particular, have been rapidly evolving, which is reflected in oncology's progress.

Machine learning and neural networks are becoming increasingly significant in precision oncology and system medicine. The combination of imaging data with clinical and molecular data opens up a world of possibilities. Radiogenomics, for instance, is a new field focused on multidimensional data processing. It can also benefit from AI advancements.

Thus, the increased adoption of automated systems acts as an opportunity for the growth of this market.

Restraint/Challenge

  • Lack of sufficient financial support from health insurance policies

To achieve their objectives, health systems require financial resources. Human resources, hospital care, and medications are the most expensive aspects of most healthcare systems. In most tropical countries, health care is funded through a combination of government, private (mainly out-of-pocket) spending, and international help.

Healthcare finance remains a key concern for low- and lower-middle-income countries. Many upper-middle-income countries in Latin America, Africa, and Asia have been able to establish health finance arrangements that cover large segments of their populations. These measures enable access to health care while also protecting individuals from catastrophic debt incurred as a result of that access. Finance, on the other hand, is a major obstacle to health care delivery in low-income countries (the bulk of which are in Sub-Saharan Africa).

Thus, the lack of sufficient financial support from health insurance policies acts as a restraint to market's growth.

Recent Developments

  • In October 2022, General Electric Company collaborated with several research institutes such as the University of Cambridge Hospitals, Sophia Genetics, and earlier with Optellum to use imaging data in collaboration with Artificial intelligence. This will help to reduce the diagnosing time of several cancers and help to provide personalized care to patients. This has helped the company to widen its horizons in cancer diagnostics
  • In March 2020, Thermo Fisher Scientific Inc. announced that it would be acquiring QIAGEN, a Netherland-based molecular diagnostics and healthcare company. This acquisition by the company will increase its product portfolio in the market, leading to increased revenue in future

Middle East and Africa Gastric Cancer Diagnostics Market Scope

The Middle East and Africa gastric cancer diagnostics market is segmented into nine notable segments based on product type, diagnostic type, age group, disease type, stage, gender, sample, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

PRODUCT TYPE

  • Instruments
  • Reagents & Consumables
  • Services

On the basis of product type, the market is segmented into instruments, reagents & consumables, and services.

DIAGNOSTIC TYPE

  • Confirmatory Test
  • Gastric Cancer Screening Tests/Physical Exam

On the basis of diagnostics type, the market is segmented into gastric cancer screening tests/physical exam and confirmatory tests.

AGE GROUP

  • Adult
  • Pediatric
  • Geriatrics

On the basis of age group, the market is segmented into adult, pediatric, and geriatrics.

TYPE

  • Intestinal Or Diffuse Adenocarcinoma
  • Carcinoid Tumor
  • Gastrointestinal Stromal Tumor (GIST)
  • Gastric Lymphoma
  • Others

On the basis of type, the market is segmented into intestinal or diffuse adenocarcinoma, carcinoid tumor, gastrointestinal stromal tumor (GIST), gastric lymphoma, and others.

STAGE

  • Stage 0
  • Stage I
  • Stage II
  • Stage III

On the basis of stage, the market is segmented into stage 0, stage I, stage II, and stage III.

GENDER

  • Male
  • Female

On the basis of gender, the market is segmented into male and female.

SAMPLE TYPE

  • Blood
  • Tissue
  • Urine
  • Stool

On the basis of sample type, the market is segmented into blood, tissue, urine, and stool.

END USER​​​​​​​

  • Diagnostic Laboratories
  • Hospitals
  • Cancer Research Institutes
  • Oncology Specialty Clinics
  • Others

On the basis of end users, the market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others.

DISTRIBUTION CHANNEL

  • Direct Tenders
  • Retail Sales

On the basis of distribution channel, the market is segmented into direct tender and retail sales.

Middle East and Africa Gastric Cancer Diagnostics Market Regional Analysis/Insights

يتم تقسيم سوق تشخيص سرطان المعدة في الشرق الأوسط وأفريقيا إلى تسعة قطاعات بارزة بناءً على نوع المنتج ونوع التشخيص والفئة العمرية ونوع المرض والمرحلة والجنس والعينة والمستخدم النهائي وقناة التوزيع. 

الدول التي يغطيها تقرير السوق هذا هي جنوب أفريقيا والمملكة العربية السعودية والإمارات العربية المتحدة ومصر وإسرائيل وبقية دول الشرق الأوسط وأفريقيا.

ومن المتوقع أن تهيمن جنوب أفريقيا في عام 2023 بسبب ارتفاع الحاجة إلى الاتصالات الفعالة والمستجيبة في مجال الرعاية الصحية.

كما يقدم قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغييرات في التنظيم في السوق محليًا والتي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. تعد نقاط البيانات مثل المبيعات الجديدة ومبيعات الاستبدال والتركيبة السكانية للدولة والقوانين التنظيمية ورسوم الاستيراد والتصدير من بين المؤشرات الرئيسية المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود وتوافر العلامات التجارية في الشرق الأوسط وأفريقيا والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية وتأثير قنوات المبيعات أثناء تقديم تحليل تنبؤي لبيانات الدولة.

تحليل المنافسة وحصة سوق تشخيص سرطان المعدة

يقدم المشهد التنافسي لسوق تشخيص سرطان المعدة في الشرق الأوسط وأفريقيا تفاصيل حسب المنافسين. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، ومواقع الإنتاج والمرافق، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وموافقات المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق، ومنحنى خط حياة نوع المنتج. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركة على سوق تشخيص سرطان المعدة.

بعض اللاعبين الرئيسيين العاملين في سوق تشخيص سرطان المعدة في الشرق الأوسط وأفريقيا هم BIOMERIEUX، Myriad Genetics، Inc.، Vela Diagnostics، Abbott، Thermo Fisher Scientific Inc.، F. Hoffmann-La Roche Ltd، General Electric، Agilent Technologies، Inc.، Biohit Oyj، DiaSorin SpA، Paragon Genomics، Inc.، و QIAGEN وغيرها.

 


SKU-

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

  • لوحة معلومات تحليل البيانات التفاعلية
  • لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
  • إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
  • تحليل المنافسين باستخدام لوحة معلومات تفاعلية
  • آخر الأخبار والتحديثات وتحليل الاتجاهات
  • استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
طلب التجريبي

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL'S MODEL

4.2 PORTER'S 5 FORCES

4.3 EPIDEMIOLOGY

4.4 BRAND ANALYSIS

4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET

4.6 INDUSTRY INSIGHTS:

5 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA

6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING

6.1.3 INCREASE IN THE GERIATRIC POPULATION

6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS

6.2 RESTRAINTS

6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST

6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES

6.3 OPPORTUNITIES

6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS

6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS

6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS

6.4 CHALLENGES

6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES

6.4.2 LIMITATIONS OF RADIATION TESTS

7 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 REAGENTS & CONSUMABLES

7.2.1 KITS

7.2.1.1 DNA POLYMERASE KITS

7.2.1.2 PCR KITS

7.2.1.3 NUCLEIC ACID ISOLATION KITS

7.2.1.4 OTHERS

7.2.2 REAGENTS

7.2.2.1 ASSAYS

7.2.2.2 BUFFERS

7.2.2.3 PRIMERS

7.2.2.4 OTHERS

7.3 INSTRUMENTS

7.4 SERVICES

8 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE

8.1 OVERVIEW

8.2 CONFIRMATORY TEST

8.2.1 IMAGING TESTS

8.2.1.1 PET SCAN/CT SCAN

8.2.1.2 CT SCAN

8.2.1.3 ULTRASOUND

8.2.1.4 MRI

8.2.1.5 X-RAY

8.2.2 BIOMARKER

8.2.2.1 DNA BIOMARKER

8.2.2.2 RNA BIOMARKER

8.2.2.3 PROTEIN BIOMARKER

8.2.3 BIOPSY

8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM

9 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP

9.1 OVERVIEW

9.2 GERIATRICS

9.3 ADULT

9.4 PEDIATRIC

10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE

10.1 OVERVIEW

10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA

10.3 CARCINOID TUMOR

10.4 GASTROINTESTINAL STROMAL TUMOR

10.5 GASTRIC LYMPHOMA

10.6 OTHERS

11 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE

11.1 OVERVIEW

11.2 STAGE I

11.2.1 STAGE IA

11.2.2 STAGE IB

11.3 STAGE II

11.3.1 STAGE IIA

11.3.2 STAGE IIB

11.4 STAGE III

11.4.1 STAGE IIIA

11.4.2 STAGE IIIB

11.4.3 STAGE IIIC

11.5 STAGE 0

12 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER

12.1 OVERVIEW

12.2 MALE

12.3 FEMALE

13 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE

13.1 OVERVIEW

13.2 STOOL

13.3 TISSUE

13.4 BLOOD

13.5 URINE

14 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 DIAGNOSTIC LABORATORIES

14.4 CANCER RESEARCH INSTITUTES

14.5 ONCOLOGY SPECIALTY CLINICS

14.6 OTHERS

15 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDERS

15.3 RETAIL SALES

16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION

16.1 MIDDLE EAST AND AFRICA

16.1.1 SOUTH AFRICA

16.1.2 SAUDI ARABIA

16.1.3 U.A.E

16.1.4 EGYPT

16.1.5 ISRAEL

16.1.6 REST OF MIDDLE EAST AND AFRICA

17 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 F. HOFFMANN-LA ROCHE LTD

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 GENERAL ELECTRIC

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 ABBOTT

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 QIAGEN

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 MYRIAD GENETICS, INC.

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 ACON LABORATORIES, INC.

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 ADVACARE PHARMA

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 AGILENT TECHNOLOGIES, INC.

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 BIOMÉRIEUX

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 BIOCEPT, INC.

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 BIOHIT OYJ

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 DIASORIN S.P.A

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 ENDOFOTONICS PTE LTD

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 FOUNDATION MEDICINE, INC.

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENTS

19.15 FUJIREBIO (AN H.U. GROUP COMPANY)

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 MIRXES PTE LTD.

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 PARAGON GENOMICS, INC.

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 TECO DIAGNOSTICS

19.18.1 COMPANY SNAPSHOT

19.18.2 PRODUCT PORTFOLIO

19.18.3 RECENT DEVELOPMENT

19.19 THERMO FISHER SCIENTIFIC INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENTS

19.2 VELA DIAGNOSTICS

19.20.1 COMPANY SNAPSHOT

19.20.2 PRODUCT PORTFOLIO

19.20.3 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

List of Table

TABLE 1 APPROVED COMPANION DIAGNOSTIC DEVICE

TABLE 2 THE BELOW-MENTIONED LIST SHOWS THE COST OF PET SCAN FOR CANCER DIAGNOSIS IN DIFFERENT REGIONS ACROSS THE GLOBE-

TABLE 3 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA REAGENT AND CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA INSTRUMENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA SERVICES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA GERIATRICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA ADULT IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA PEDIATRIC IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA INTESTINAL OR DIFFUSE ADENOCARCINOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA CARCINOID TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA GASTROINTESTINAL STROMAL TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA GASTRIC LYMPHOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA STAGE 0 IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA MALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA FEMALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA STOOL IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA TISSUE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA BLOOD IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA URINE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA HOSPITALS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA DIAGNOSTIC LABORATORIES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA CANCER RESEARCH INSTITUTES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA ONCOLOGY SPECIALTY CLINICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA DIRECT TENDERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA RETAIL SALES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 58 MIDDLE EAST & AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 62 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 63 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 64 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 65 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 66 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 67 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 68 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 69 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 70 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 71 SOUTH AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 72 SOUTH AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 73 SOUTH AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 74 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 75 SOUTH AFRICA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 76 SOUTH AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 77 SOUTH AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 78 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 79 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 80 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 81 SOUTH AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 82 SOUTH AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 83 SOUTH AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 84 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 85 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 86 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 87 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 88 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 89 SAUDI ARABIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 90 SAUDI ARABIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 91 SAUDI ARABIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 92 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 93 SAUDI ARABIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 94 SAUDI ARABIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 95 SAUDI ARABIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 96 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 97 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 98 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 99 SAUDI ARABIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 100 SAUDI ARABIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 101 SAUDI ARABIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 102 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 103 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 104 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 105 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 106 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 107 U.A.E REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 108 U.A.E KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 109 U.A.E REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 110 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 111 U.A.E CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 112 U.A.E IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 113 U.A.E BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 114 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 115 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 116 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 117 U.A.E STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 118 U.A.E STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 119 U.A.E STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 120 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 121 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 122 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 123 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 124 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 125 EGYPT REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 126 EGYPT KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 127 EGYPT REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 128 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 129 EGYPT CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 130 EGYPT IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 131 EGYPT BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 132 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 133 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 134 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 135 EGYPT STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 136 EGYPT STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 137 EGYPT STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 138 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 139 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 140 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 141 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 142 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 143 ISRAEL REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 144 ISRAEL KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 145 ISRAEL REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 146 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 147 ISRAEL CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 148 ISRAEL IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 149 ISRAEL BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)

TABLE 150 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 151 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)

TABLE 152 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 153 ISRAEL STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 154 ISRAEL STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 155 ISRAEL STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)

TABLE 156 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 157 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 158 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 159 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 160 REST OF MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS. REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MARKET END COVERAGE GRID

FIGURE 11 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 INCREASE IN THE INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 13 REAGENTS AND CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES, OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET

FIGURE 15 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022

FIGURE 16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 17 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 18 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 19 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2022

FIGURE 20 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION)

FIGURE 21 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, CAGR (2023-2030)

FIGURE 22 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, LIFELINE CURVE

FIGURE 23 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022

FIGURE 24 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 25 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 26 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 27 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2022

FIGURE 28 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2023-2030 (USD MILLION)

FIGURE 29 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, CAGR (2023-2030)

FIGURE 30 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 31 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2022

FIGURE 32 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2023-2030 (USD MILLION)

FIGURE 33 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2023-2030)

FIGURE 34 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE

FIGURE 35 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2022

FIGURE 36 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)

FIGURE 37 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 38 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 39 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2022

FIGURE 40 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)

FIGURE 41 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2023-2030)

FIGURE 42 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 43 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 44 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 45 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 46 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 48 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 49 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 50 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 52 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 53 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 54 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 55 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)

FIGURE 56 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

View Detailed Information Right Arrow

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.

منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.

التخصيص متاح

تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.

Frequently Asked Questions

The Middle East and Africa Gastric Cancer Diagnostics Market is projected to grow at a CAGR of 7.4% during the forecast period by 2030.
The future market value of the Middle East and Africa Gastric Cancer Diagnostics Market is expected to reach USD 69.63 million by 2030.
The major players in the Middle East and Africa Gastric Cancer Diagnostics Market are BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., etc.
The countries covered in the Middle East and Africa Gastric Cancer Diagnostics Market are Saudi Arabia, South Africa, U.A.E, Israel, Egypt, and rest of Middle East and Africa.